The State Scientific Center of Virology and Biotechnology "Vector" of Rospotrebnadzor has completed post-registration clinical studies of the EpiVacCorona coronavirus vaccine among the elderly. This was stated by and. about. Deputy General Director for Scientific and Methodological Work and International Cooperation of the State Research Center "Vector" Tatiana Nepomnyashchikh, writes TASS. “Currently, just a few days ago, we completed post-registration clinical studies on volunteers of the age group 60+,” Nepomnyashchikh said. According to her, this is the most vulnerable group of people that must be protected in the first place. The Russian Federation became the first country in the world to register a vaccine against COVID-19. The drug was developed by NITsEM named after Gamaleya in cooperation with the Russian Direct Investment Fund. It was named "Sputnik V". Later, the Novosibirsk Center "Vector" registered the second Russian vaccine against the coronavirus "EpiVacCorona". Earlier it became known that immunity after vaccination with "EpiVacCorona" will persist for a year.
